UBS has initiated coverage of Cicor Technologies with a “buy” rating and a CHF173 price target, positioning the Swiss firm as a key player in Europe's growing defense sector. This positive outlook follows expectations of a 16% CAGR in European defense equipment budgets through 2030. The brokerage projects a return to organic growth in 2026, driven by strengthened defense demand.

The investment bank anticipates organic growth of about 7% in 2027 and 2028, aligning with Cicor's mid-term targets. UBS also pointed to potential improvements in profitability, estimating a 200 basis point increase in adjusted EBITDA margins by 2028. This positive assessment of Cicor comes after a period of investor concern following a December 2025 profit warning.

UBS sees further acquisition opportunities, given Cicor's projected net debt levels. The firm's valuation, trading at approximately 15x 2026 earnings, is about 20% below its Swiss industrial peers, according to UBS. The brokerage's base-case scenario assumes an 11% revenue CAGR and a 17% EBITDA CAGR between 2025 and 2028.

Ultimately, the analysts' discounted-cash-flow approach uses long-term growth of 2%, an 11% EBITDA margin, and an 8.5% weighted average cost of capital. UBS's positive assessment and the expected boost from the defense sector make Cicor a compelling investment. Investors will be watching for further developments in the company's M&A strategy.